Table 5. HRs and 95% CIs of breast cancer by HER2 status in relation to quartiles of B vitamin intake in ORDET women.
| HER2+ | HER2- | |||
|---|---|---|---|---|
| Cases/person-year | Multivariable HR (95% CI)* | Cases/person-year | Multivariable HR (95% CI) | |
| Thiamine | ||||
| I | 17/33560 | 1 | 90/34183 | 1 |
| II | 20/33817 | 0.87 (0.44–1.75) | 60/34132 | 0.66 (0.46–0.94) |
| III | 11/33632 | 0.38 (0.55–0.92) | 61/34013 | 0.67 (0.44–1.01) |
| IV | 14/34055 | 0.31 (0.10–0.99) | 62/34404 | 0.66 (0.38–1.15) |
| P trend** | 0.017 | 0.120 | ||
| Continuous # | 0.88 (0.51–1.52) | 0.80 (0.61–1.04) | ||
| P for Heterogeneity## | 0.720 | |||
| Riboflavin | ||||
| I | 23/33756 | 1 | 97/34356 | 1 |
| II | 14/33664 | 0.44 (0.22–0.89) | 60/34054 | 0.58 (0.41–0.82) |
| III | 10/33792 | 0.26 (0.11–0.61) | 61/34151 | 0.57 (0.39–0.83) |
| IV | 15/33852 | 0.28 (0.10–0.74) | 55/24171 | 0.47 (0.29–0.76) |
| P trend | 0.004 | 0.002 | ||
| Continuous | 0.67 (0.43–1.04) | 0.82 (0.67–1.00) | ||
| P for Heterogeneity## | 0.430 | |||
| Niacin | ||||
| I | 15/33401 | 1 | 76/33911 | 1 |
| II | 14/33792 | 0.85 (0.40–1.82) | 79/34334 | 1.04 (0.75–1.46) |
| III | 17/33842 | 1.00 (0.45–2.22) | 59/34153 | 0.80 (0.54–1.19) |
| IV | 16/34029 | 0.89 (0.33–2.36) | 59/34335 | 0.82 (0.51–1.32) |
| P trend | 0.923 | 0.252 | ||
| Continuous | 0.91 (0.61–1.36) | 0.82 (0.67–1.00) | ||
| P for Heterogeneity## | 0.638 | |||
| Vitamin B6 | ||||
| I | 16/33542 | 1 | 87/34113 | 1 |
| II | 18/33653 | 0.96 (0.47–1.95) | 72/34120 | 0.79 (0.56–1.09) |
| III | 11/33822 | 0.55 (0.23–1.30) | 56/34163 | 0.59 (0.40–0.87) |
| IV | 17/34047 | 0.73 (0.27–1.96) | 58/34337 | 0.58 (0.36–0.94) |
| P trend | 0.324 | 0.011 | ||
| Continuous | 0.74 (0.48–1.14) | 0.77 (0.63–0.95) | ||
| P for Heterogeneity## | 0.862 | |||
| Folate | ||||
| I | 16/33530 | 1 | 81/34106 | 1 |
| II | 16/33766 | 0.89 (0.43–1.85) | 74/34238 | 0.89 (0.64–1.25) |
| III | 15/33954 | 0.80 (0.36–1.76) | 67/34306 | 0.79 (0.55–1.14) |
| IV | 15/33813 | 0.78 (0.31–1.98) | 51/34083 | 0.60 (0.38–0.94) |
| P trend | 0.563 | 0.028 | ||
| Continuous | 0.92 (0.64–1.33) | 0.87 (0.73–1.04) | ||
| P for Heterogeneity## | 0.772 | |||
* Adjusted for height, waist-hip-ratio, age at menarche, menopausal status, oral contraceptive use, parity, education, family history of breast cancer, energy intake, and alcohol intake.
** Tests for linear trend were calculated by assigning an ordinal number to each quartile.
# HR of developing breast cancer per 1 SD increase in vitamin intake.
## HER2+ vs. HER2-.